• News Releases
  • Mar. 31, 2020 (PDF/51KB)Licensing
    Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
  • Mar. 31, 2020 (PDF/85KB)CSR
    Donations to the Kitasato Institute's Project for COVID-19 for Early Identification of Therapeutic Medicine for its Treatment
  • Mar. 25, 2020 (PDF/164KB)Products
    Sumitomo Dainippon Pharma Announces the Approval of RETHIO for an Additional Indication of Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
  • Mar. 25, 2020 (PDF/107KB)Products
    Sumitomo Dainippon Pharma Announces Approval of Atypical Antipsychotic Agent, LATUDA Tablets in Japan
  • Mar. 18, 2020 (PDF/83KB)Corporate
    Sumitomo Dainippon Pharma Announces Change in Executive Officer and Other Key Position